Clinical Trial Update: The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating whether early administration of Alendronate after hip fracture can prevent bone loss in people with osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• alendronate (alendronate)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Osteoporosis | Phase 3 | Status: UNKNOWN